Ignite Creation Date:
2025-12-25 @ 2:45 AM
Ignite Modification Date:
2026-06-19 @ 9:19 AM
Study NCT ID:
NCT05903833
Status:
RECRUITING
Last Update Posted:
2025-09-09
First Post:
2023-05-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
Sponsor:
AGO Research GmbH
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
AGO-Vulva 1
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None